CSPC Pharmaceutical Group Ltd
HKEX:1093
CSPC Pharmaceutical Group Ltd
Total Equity
CSPC Pharmaceutical Group Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Total Equity
¥32.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Total Equity
¥28.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Total Equity
¥14B
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
18%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Total Equity
¥45.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Total Equity
¥3.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Total Equity
¥3.9B
|
CAGR 3-Years
127%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
CSPC Pharmaceutical Group Ltd
Glance View
CSPC Pharmaceutical Group Ltd., a prominent player in the pharmaceutical industry, has charted a strategic path focused on innovation and a diversified portfolio. The company, with its roots in China, has emerged as a formidable force by blending traditional pharmaceutical manufacturing with a strong emphasis on research and development. CSPC's journey is characterized by a commitment to developing high-quality generic drugs, innovative therapeutics, and nutritional products. The company's core business revolves around the production and sale of a wide range of pharmaceuticals, including cardiovascular drugs, oncology treatments, and central nervous system therapies. By leveraging advanced technology and robust research initiatives, CSPC consistently delivers solutions that address both common and complex healthcare needs across the globe. With a strategic focus on both domestic and international markets, CSPC Pharmaceutical Group capitalizes on its extensive distribution network to maximize reach and impact. The company has made significant investments in its production capabilities to maintain stringent quality standards while achieving cost efficiency. Furthermore, CSPC's earnings are bolstered by its expanding pipeline of innovative drugs, developed in-house and through strategic collaborations, which aims to capture emerging therapeutic areas. Overall, CSPC's blend of traditional pharmaceutical expertise, a focus on innovation, and strategic market positioning enables it to maintain a strong operational foothold and to consistently drive revenue growth in an ever-evolving industry landscape.
See Also
What is CSPC Pharmaceutical Group Ltd's Total Equity?
Total Equity
32.3B
CNY
Based on the financial report for Dec 31, 2024, CSPC Pharmaceutical Group Ltd's Total Equity amounts to 32.3B CNY.
What is CSPC Pharmaceutical Group Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
17%
Over the last year, the Total Equity growth was -3%. The average annual Total Equity growth rates for CSPC Pharmaceutical Group Ltd have been 7% over the past three years , 12% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet